Inclusion body myositis: from genetics to clinical trials

被引:11
|
作者
Nagy, Sara [1 ,2 ]
Khan, Alaa [1 ,3 ]
Machado, Pedro M. [2 ,4 ]
Houlden, Henry [1 ]
机构
[1] UCL, Dept Neuromuscular Dis, UCL Queen Sq Inst Neurol, London, England
[2] Univ Basel, Univ Hosp Basel, Dept Neurol, Basel, Switzerland
[3] King Abdullah Med City Makkah, Mol Diagnost Unit, Clin Lab Dept, Mecca, Saudi Arabia
[4] UCL, Ctr Rheumatol, Div Med, London, England
关键词
Sporadic inclusion body myositis; Hereditary inclusion body myositis; Genetic susceptibility; Inflammation; Neurodegeneration; Clinical trials; Gene therapy; RIMMED VACUOLES; DOUBLE-BLIND; RISK LOCI; MYOPATHY; MITOCHONDRIAL; ASSOCIATION; BIMAGRUMAB; EFFICACY; REVEALS; SAFETY;
D O I
10.1007/s00415-022-11459-3
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
Inclusion body myositis (IBM) belongs to the group of idiopathic inflammatory myopathies and is characterized by a slowly progressive disease course with asymmetric muscle weakness of predominantly the finger flexors and knee extensors. The disease leads to severe disability and most patients lose ambulation due to lack of curative or disease-modifying treatment options. Despite some genes reported to be associated with hereditary IBM (a distinct group of conditions), data on the genetic susceptibility of sporadic IBM are very limited. This review gives an overview of the disease and focuses on the current genetic knowledge and potential therapeutic implications.
引用
收藏
页码:1787 / 1797
页数:11
相关论文
共 50 条
  • [1] Inclusion body myositis: from genetics to clinical trials
    Sara Nagy
    Alaa Khan
    Pedro M. Machado
    Henry Houlden
    Journal of Neurology, 2023, 270 : 1787 - 1797
  • [2] Genetics in inclusion body myositis
    Rothwell, Simon
    Lilleker, James B.
    Lamb, Janine A.
    CURRENT OPINION IN RHEUMATOLOGY, 2017, 29 (06) : 639 - 644
  • [3] Inclusion body myositis - pathomechanism and lessons from genetics
    Murnyak, Balazs
    Bodoki, Levente
    Vincze, Melinda
    Griger, Zoltan
    Csonka, Tamas
    Szepesi, Rita
    Kurucz, Andrea
    Danko, Katalin
    Hortobagyi, Tibor
    OPEN MEDICINE, 2015, 10 (01): : 188 - 193
  • [4] Advances in inclusion body myositis: genetics, pathogenesis and clinical aspects
    Needham, Merrilee
    Mastaglia, Frank
    EXPERT OPINION ON ORPHAN DRUGS, 2017, 5 (05): : 431 - 443
  • [5] Genetics of inclusion-body myositis
    Needham, M.
    Mastaglia, F. L.
    Garlepp, M. J.
    MUSCLE & NERVE, 2007, 35 (05) : 549 - 561
  • [7] New Developments in the Genetics of Inclusion Body Myositis
    Kyla A. Britson
    Stephanie Y. Yang
    Thomas E. Lloyd
    Current Rheumatology Reports, 2018, 20
  • [8] New Developments in the Genetics of Inclusion Body Myositis
    Britson, Kyla A.
    Yang, Stephanie Y.
    Lloyd, Thomas E.
    CURRENT RHEUMATOLOGY REPORTS, 2018, 20 (05)
  • [9] Challenges for Treatment Trials of Inclusion Body Myositis
    Roy, Bhaskar
    Griggs, Robert C.
    NEUROLOGY, 2021, 96 (12) : 555 - 556
  • [10] A prospective natural history study of inclusion body myositis: Implications for clinical trials
    Rose, MR
    McDermott, MP
    Thornton, CA
    Palenski, C
    Martens, WB
    Griggs, RC
    NEUROLOGY, 2001, 57 (03) : 548 - 550